CClinicalTrials.gg
CompletedNCT02873273Updated Oct 1, 2018

Study of a Steroid Delivery System for Pain Relief Treatment in Patients With Knee Osteoarthritis

A Phase 1 interventional study of Dexamethasone in Osteoarthritis, Knee, sponsored by Mark Figgie. Completed at 1 site in United States. Open to participants aged 40 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-10-01.

Sponsored by Mark Figgie · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
40 Years to 99 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether a longer duration, controlled, sustained release dexamethasone delivery system would be more effective in helping patients with osteoarthritis reduce their pain, remain functional, and delay their need for knee replacement.

Read the detailed description

The objectives of the study are to assess the dexamethasone delivery system for:

  • Safety and tolerability
  • Efficacy

Formal statistical analysis to compare treatment groups will not be performed due to the small number of participants in this pilot study. Summary statistics will be assessed using the short form of the knee injury and osteoarthritis outcome score (KOOS JR) surveys and questionnaires to assess pain intensity, pain medication consumption and wound assessment.

02

Conditions studied

  • Osteoarthritis, Knee
03

In context

Osteoarthritis

4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.

This study's enrollment of 6 is below the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

This is the only study on the registry with Mark Figgie as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male or female ≥ 40 years of age at time of consent
  • Diagnosis of unilateral or bilateral knee osteoarthritis for at least 6 months prior to screening with confirmation of osteoarthritis according to the American College of Rheumatology Criteria for Classification of Idiopathic Osteoarthritis of the Knee (clinical and radiological) based on an X-ray performed within 6 months prior to screening or during the screening period
  • Kellgren - Lawrence grade ≥2 on weight bearing anteroposterior femorotibial radiograph performed within 6 months prior to or during screening period
  • Mean score of ≥ 5 and ≤ 10 on the 24 hour average pain score (0 - 10 Numeric Rating System) during the screening period
  • Body mass index (BMI) ≤ 40 kg/m2
  • Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions
  • Willingness to stop all pain medications except acetaminophen and paracetamol 14 days prior to implantation

Exclusion criteria

Exclusion Criteria:

  • Fibromyalgia, chronic pain syndrome, or other concurrent medical or arthritic conditions which could interfere with the evaluation of the index knee
  • History of inflammatory arthritis including rheumatoid arthritis, juvenile inflammatory arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, reactive arthritis
  • Hemophilia
  • Achondroplasia
  • History of infection in the index joint
  • Intra-articular corticosteroid (investigational or marketed) in any joint within three months of screening
  • Intra-articular hyaluronic acid (investigational or marketed) in the index knee within three months of screening
  • Oral, inhaled, and intranasal corticosteroids (investigational or marketed) within one month of screening
  • Prior arthroscopic or open surgery of the index knee within 12 months of screening
  • Planned / anticipated surgery of the index knee during the study period
  • Active or history of malignancy within the last five years, with the exception of resected basal cell carcinoma, squamous cell carcinoma of the skin, or resected cervical atypia or carcinoma in situ
  • Insulin dependent diabetes
  • History of or active Cushing's syndrome
  • Skin breakdown at index knee where procedure would take place
  • Women of child-bearing potential
  • Case history related to motor vehicle accident or workers compensation
  • Presence of hardware in the index knee (e.g. screws, plates)
  • Immunocompromised patients (TB, HIV, etc.)
  • Allergic reactions to acetaminophen and paracetamol
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Dexamethasone delivery system

    Drug: Dexamethasone

Interventions

  • DrugDexamethasone

    Sustained delivery system containing 5.0 mg of dexamethasone programmed to release an estimated 10 μg per day

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent adverse events

    Time frame: Through 24 weeks

  2. Change from baseline in weekly mean of the pain intensity score

    Using a numeric rating scale for pain with a scale of 0 (no pain) to 10 (worst pain imaginable) at rest, during activity, and at night

    Time frame: Weeks 12, 24

Secondary outcomes

  1. Change from baseline in weekly mean of the pain intensity score

    Using a numeric rating scale for pain with a scale of 0 (no pain) to 10 (worst pain imaginable) at rest, during activity, and at night

    Time frame: Weekly through 24 weeks

  2. Time of onset of pain relief

    Time frame: Weekly through 24 weeks

  3. Change from baseline in KOOS-JR score (stiffness)

    Using a response scale of none, mild, moderate, severe, and extreme

    Time frame: Over 1, 2, 4, 8, 12, 24 weeks post treatment

  4. Change from baseline in KOOS-JR score (pain)

    Using a response scale of none, mild, moderate, severe, and extreme

    Time frame: Over 1, 2, 4, 8, 12, 24 weeks post treatment

  5. Change from baseline in KOOS-JR score (function)

    Using a response scale of none, mild, moderate, severe, and extreme

    Time frame: Over 1, 2, 4, 8, 12, 24 weeks post treatment

  6. Change in patient's global impression of scores assessed via office visits

    Using a numeric rating scale for pain with a scale of 0 (no pain) to 10 (worst pain imaginable)

    Time frame: Weeks 4, 12, 24

  7. Change in clinical observer's global impression of scores assessed via office visits

    Using a numeric rating scale for pain with a scale of 0 (no pain) to 10 (worst pain imaginable)

    Time frame: Weeks 4, 12, 24

  8. Percent of responders (defined as patients with high improvement in pain or function) according to OMERACT-OARSI criteria

    Time frame: Weeks 1, 2, 4, 8, 12, 24

  9. Average weekly consumption of rescue medications

    Time frame: Through 24 weeks

  10. Average total consumption of rescue medications

    Time frame: Through 24 weeks

07

Study locations

1 site
  • Hospital for Special Surgery
    New York, New York 10021, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02873273
Lead sponsor
Mark Figgie
Collaborators
Hospital for Special Surgery, New York
Responsible party
Mark Figgie (Chief of the Surgical Arthritis Service, Hospital for Special Surgery, New York) — Sponsor-investigator
First posted
Aug 19, 2016
Start date
Oct 14, 2016
Primary completion
Sep 21, 2017
Completion
Sep 21, 2017
Last update
Oct 1, 2018

Study contacts

Mark Figgie, MD
principal investigator · Hospital for Special Surgery, New York

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion